Reached your goal on Wegovy? Here’s what maintenance looks like

You reached your goal weight on Wegovy! Congratulations are in order. You have climbed the mountaintop and taken a deep breath while overlooking the valley below. All of the months of diligence, of sticking to your regiment, have paid off.

But now you face another stark reality, because as tough as it is to lose weight, keeping it off may be even tougher. Now you’re asking a question your prescriber may not have a clean answer for:  What’s the maintenance dose?

The honest answer is more nuanced than the one you’ll get from a Reddit thread. Here’s what the clinical trials actually show, what “maintenance” means in real obesity medicine, and how a 34-year-old practice handles the conversation.

What “Maintenance Dose” Actually Means

There are two different questions hiding inside the phrase “Wegovy maintenance dose,” and it helps to separate them.

1. Once I reach goal weight, what dose do I keep taking?

The clinical answer from the FDA labeling and the trial data: the dose you reached goal weight at. Wegovy was designed and studied for continued use at therapeutic doses — typically 1.7 mg or 2.4 mg weekly, and now up to 7.2 mg weekly under the Wegovy HD approval (March 2026).

2. Can I take it less often, at a lower dose, or eventually stop?

This is the question that actually has clinical nuance, and where the practice you’re working with starts to matter. The trial data is clear that stopping the medication entirely causes weight regain. The data is less clear — but increasingly supportive — that some patients can space out their injections or step down to lower doses while maintaining their loss.

We’ll cover both. Let’s start with what the trials show.

The STEP 4 Data (Semaglutide)

This is the trial that defined the maintenance question for semaglutide.

In STEP 4 (Rubino et al., JAMA 2021), all patients from week 0 to week 20 reached the full 2.4 mg weekly dose and lost an average of 10.6% of body weight in those 20 weeks. At week 20, they were randomized: half continued the 2.4 mg dose, half switched to placebo.

The result at week 68:

• Continued semaglutide 2.4 mg: lost an additional 7.9% of body weight (total loss from baseline: 17.4%)
• Switched to placebo: regained 6.9% of body weight (net loss from baseline: 5.0%)

That’s a roughly 15-point difference in body weight between the two groups at the end of the trial, attributable entirely to whether the medication continued.

The interpretation that matters clinically: semaglutide is doing active work at the maintenance phase. It’s not just holding ground — it’s continuing to push weight down. Stopping doesn’t “lock in” the loss. The pharmacology assumes continued use.

The SURMOUNT-4 Data (Tirzepatide)

The tirzepatide equivalent was even more dramatic.

In SURMOUNT-4 (Aronne et al., *JAMA* 2024), all patients ran an open-label phase reaching maximum tolerated dose (10 mg or 15 mg weekly) for 36 weeks, losing an average of 20.9% of body weight in that phase. They were then randomized at week 36 to continued tirzepatide or placebo, and followed for another 52 weeks.

The result at week 88:

• Continued tirzepatide: :Lost an additional 5.5% of body weight (total loss from baseline: ~25%)
• Switched to placebo: Regained 14.0% of body weight (net loss from baseline: ~9%)

A 19-point swing between continued and discontinued groups.

The pattern is the same as semaglutide, just larger. The medication is actively maintaining the loss. Stopping it gives most of the loss back over the following year.

What This Means for Your Maintenance Dose

The trial data establishes a clear baseline answer: the maintenance dose is the therapeutic dose you reached, continued indefinitely.

That’s not the answer most patients want to hear. They want to hear “you can take less,” or “you can stop in six months,” or “you can space out your shots.” Some of those things are clinically reasonable. Some are not.

Here’s how the conversation actually breaks down in our practice.

This is why obesity medicine treats obesity as a chronic disease. The medication doesn’t cure; it manages. The same way blood pressure medication manages hypertension. The same way insulin manages diabetes. Patients on those medications don’t stop when their numbers normalize. They continue, because the underlying condition is still there. Obesity is no different. The trials are just confirming what obesity medicine has known for decades.

The regain isn’t immediate. In both trials, patients who stopped saw weight return gradually over roughly 12 months with the steepest regain in the first three to four months. That gradual onset is what makes it dangerous. By the time most patients notice the trajectory, the weight has already accumulated past where it can be easily reversed.

What Maintenance Looks Like in Real Practice

There are three patterns we use clinically, depending on the patient’s response, goals, and tolerance for the medication. No two patients get the same maintenance protocol.

Pattern 1: Continue at the therapeutic dose
This is what the trial data supports most strongly. The patient stays on the dose they reached their goal at (1.7 mg, 2.4 mg, or 7.2 mg of semaglutide; 10 mg or 15 mg of tirzepatide) and continues weekly injections indefinitely.

This is the pattern with the strongest evidence for sustained weight loss. It’s also the most expensive and the one most patients eventually want to evolve from.

Pattern 2: Step down to a lower dose
⁠For some patients — particularly those who reached goal at the maximum dose — a lower maintenance dose preserves most of the appetite suppression while reducing cost, side effects, and the burden of long-term use at maximum dose.

Until recently, this strategy was a clinical adjustment without a head-to-head trial behind it. That changed at the 2026 European Congress on Obesity. In *SURMOUNT-MAINTAIN*, Eli Lilly randomized patients who reached goal weight on their maximum tolerated tirzepatide dose into three arms: continue at max dose, step down to 5 mg, or switch to placebo. After one year:

• Continued max dose: weight loss essentially fully maintained
• Stepped down to 5 mg: weight loss largely maintained, with an average regain of about 12 pounds
• ⁠Switched to placebo: large regain, with roughly 67% of patients eventually requiring rescue therapy

⁠That 12-pound tradeoff is the answer to the question patients ask most often: What does it actually cost me to step down? On a 60-pound loss, it’s about 12 pounds back — modest compared to stopping entirely, but real.

⁠The step-down is no longer a clinical workaround but an evidence-supported strategy. A common protocol: 15 mg → 10 mg → 5 mg for tirzepatide, or 2.4 mg → 1.7 mg → 1.0 mg for semaglutide, holding for several weeks at each level and watching the scale. If weight starts creeping back, return to the previous dose.

Pattern 3: Extend the dosing interval

For patients who maintain well on a lower dose, the next step is sometimes extending the interval between injections. Once every 10 days. Once every 2 weeks. In rare cases, once a month.

This is where the practice you’re with really matters. You should not be making this adjustment on your own. The pharmacokinetics of semaglutide and tirzepatide are forgiving — they have long half-lives — but missing the window for too long causes appetite to return and the maintenance pattern to break.

What we typically tell patients exploring this path: the value of the monthly visit is partly the medication, but mostly the accountability. Knowing you’re going to be weighed, knowing you’re going to talk to your provider, knowing the relationship is still there — that’s often what’s actually holding the weight.

The Accountability Question

There’s a quiet finding in the obesity medicine literature that should change how patients think about maintenance.

A 2025 study in Obesity Medicine found that patients treated by an obesity specialist were significantly more likely to persist on GLP-1 therapy than patients in general care settings. The persistence gap shows up most clearly during the maintenance phase — when the dramatic loss has stopped and the question becomes, What now?

Maintenance is the phase where patients quit. Sometimes because:
– They think they don’t need the medication anymore;
– The cost feels harder to justify once the scale isn’t moving;
– Nobody’s in the room to walk them through what step-down protocols actually look like;
–  They achieved their weight-loss goal and think they reached the “finish line.”

The patients who hold their weight long-term are almost always the ones who didn’t try to do it alone.

The accountability isn’t a marketing line. It’s the part of the protocol the trials didn’t measure.